MichaelAPostowMD

PubMed

• Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis.
  Isabella Sala, Eleonora Pagan, Laura Pala, Chiara Oriecuia, Marco Musca, Claudia Specchia, Tommaso De Pas, Javier Cortes, Giuseppe Giaccone, Michael Postow, Richard D ...> ;Frontiers in Immunology. 2024 Jan 1
• Recent Advances in the Field of Artificial Intelligence for Precision Medicine in Patients with a Diagnosis of Metastatic Cutaneous Melanoma.
  Hayley Higgins, Abanoub Nakhla, Andrew Lotfalla, David Khalil, Parth Doshi, Vandan Thakkar, Dorsa Shirini, Maria Bebawy, Samy Ammari, Egesta Lopci, Lawrence H Schwartz...> ;Diagnostics. 2023 Nov 20
• Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.
  Paul B Chapman, Mark Klang, Michael A Postow, Ryan J Sullivan, Taha Merghoub, Sadna Budhu, Phillip Wong, Margaret K Callahan, Bin Zheng, Shoushtari, A., Zippin, J., Wo...> ;Cancer Research Communications. 2023 Dec 4
• Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes.
  Patrick T Magahis, Deepika Satish, Ngolela Esther Babady, Mini Kamboj, Michael A Postow, Monika Laszkowska, David M Faleck> ;The Oncologist. 2024 Jan 5
• A topic modeling approach reveals the dynamic T cell composition of peripheral blood during cancer immunotherapy.
  Xiyu Peng, Jasme Lee, Matthew Adamow, Colleen Maher, Michael A Postow, Margaret K Callahan, Katherine S Panageas, Ronglai Shen> ;Cell Reports Methods. 2023 Aug 28
• 14 citations
  Clonally expanded CD38cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis.
  Runci Wang, Anvita Singaraju, Kathryne E Marks, Lorien Shakib, Garrett Dunlap, Ifeoluwakiisi Adejoorin, Stinne R Greisen, Lin Chen, Aidan K Tirpack, Carlos Aude, Miria...> ;Science Immunology. 2023 Jul 28
• 2 citations
  Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
  Hong, D., Postow, M., Chmielowski, B., Sullivan, R., Patnaik, A., Cohen, E., Shapiro, G., Steuer, C., Gutierrez, M., Yeckes-Rodin, H., Ilaria, R., O'Connell, B., Peng,...> ;Clinical Cancer Research. 2023 Jun 13
• Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors.
  Deepika Satish, I-Hsin Lin, James Flory, Hans Gerdes, Michael A Postow, David M Faleck> ;The Oncologist. 2023 Dec 11
• 2 citations
  Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis.
  Yousef R Badran, Fangwen Zou, Sienna M Durbin, Barbara E Dutra, Hamzah Abu-Sbeih, Anusha S Thomas, Mehmet Altan, John A Thompson, Wei Qiao, Donna E Leet, Po-Ying Lai, ...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
• Uncovering the hidden structure of dynamic T cell composition in peripheral blood during cancer immunotherapy: a topic modeling approach.
  Xiyu Peng, Jasme Lee, Matthew Adamow, Colleen Maher, Michael A Postow, Margaret K Callahan, Katherine S Panageas, Ronglai Shen> ;Biorxiv. 2023 Apr 28
• Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.
  Kimberly Loo, Hannah L Kalvin, Katherine S Panageas, Margaret K Callahan, Paul B Chapman, Parisa Momtaz, Alexander N Shoushtari, Michael A Postow, Allison Betof Warner...> ;Pigment Cell & Melanoma Research. 2023 Apr 11
• 1 citations
  Accelerating the Evolution of Immune-Related Enterocolitis Management.
  David M Faleck, Michael Dougan, Monique Tello, Joseph E Grossman, Alan C Moss, Michael A Postow> ;Journal of Clinical Oncology. 2023 Jun 10
• 1 citations
  Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
  Rodabe N Amaria, Michael Postow, Elizabeth M Burton, Michael T Tetzlaff, Merrick I Ross, Carlos Torres-Cabala, Isabella C Glitza, Fei Duan, Denái R Milton, Klaus Busam...> ;Nature. 2023 Mar 1
• 3 citations
  Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure.
  Kathryn R Tringale, Anne S Reiner, Ryka R Sehgal, Katherine Panageas, Allison S Betof Warner, Michael A Postow, Nelson S Moss> ;CNS Oncology. 2023 Mar 1
• 4 citations
  Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
  Thomas M Atkinson, Jennifer L Hay, Soo Young Kim, Elizabeth Schofield, Michael A Postow, Parisa Momtaz, Allison Betof Warner, Alexander N Shoushtari, Margaret K Callah...> ;The Oncologist. 2023 Apr 6
• 2 citations
  Associations Between Race/Ethnicity, Language, and Enrollment on Cancer Research Studies.
  Ogochukwu M Ezeoke, Gary Brooks, Michael A Postow, Shrujal Baxi, Soo Young Kim, Bharat Narang, Lisa C Diamond> ;The Oncologist. 2023 Feb 8
• 3 citations
  Ensuring equity in the era of HLA-restricted cancer therapeutics.
  James W Smithy, Amanda Blouin, Lisa C Diamond, Michael Postow> ;Journal for Immunotherapy of Cancer. 2022 Nov 1
• 99 citations
  Neoadjuvant relatlimab and nivolumab in resectable melanoma.
  Rodabe N Amaria, Michael Postow, Elizabeth M Burton, Michael T Tetzlaff, Merrick I Ross, Carlos Torres-Cabala, Isabella C Glitza, Fei Duan, Denái R Milton, Klaus Busam...> ;Nature. 2022 Nov 1
• 2 citations
  Adjuvant checkpoint blockade following complete local therapy for melanoma metastases.
  James W Smithy, Michael A Postow> ;Lancet. 2022 Oct 1
• 1 citations
  Standardized guidelines for acral and nail unit melanoma treatment are lacking.
  Julianne M Falotico, Michael A Postow, Shari R Lipner> ;Journal of the American Academy of Dermatology. 2022 Nov 1
• 12 citations
  Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.
  Martin Schuler, Lisa Zimmer, Kevin B Kim, Jeffrey A Sosman, Paolo A Ascierto, Michael A Postow, Filip Y F L De Vos, Carla M L van Herpen, Matteo S Carlino, Douglas B J...> ;Clinical Cancer Research. 2022 Jul 15
• Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment.
  Kimberly Loo, Hannah L Kalvin, Katherine S Panageas, Vivian Park, Michael A Postow> ;The Oncologist. 2022 Sep 2
• 16 citations
  Deciphering radiological stable disease to immune checkpoint inhibitors.
  J Luo, S Wu, H Rizvi, Q Zhang, J V Egger, J C Osorio, A J Schoenfeld, A J Plodkowski, M S Ginsberg, M K Callahan, C Maher, A N Shoushtari, M A Postow, M H Voss, R R Ko...> ;Annals of Oncology. 2022 Aug 1
• 6 citations
  Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
  Krisztian Homicsko, Reinhard Dummer, Christoph Hoeller, F Stephen Hodi, James Larkin, Paolo A Ascierto, Victoria Atkinson, Caroline Robert, Michael A Postow, Sandra Re...> ;Cancers. 2022 May 5
• The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.
  Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, Andrew Futreal, Omid Hamid, Theresa LaVallee, Michael A Postow, Igor Puzanov, Jeffrey Sosman, Bernard A Fox, Patr...> ;Journal of Translational Medicine. 2022 Apr 21
• Join now to see all

Journal Articles

• Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain  
  Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
• Marked Response of a Hypermutated Adrenocorticotropic Hormone-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab  
  Michael Postow, Viviane Tabar, T Jonathan Yang, John Cuaron, Jinru Shia, Lisa M DeAngelis, The Journal of Clinical Endocrinology and Metabolism
• Melanoma Brain Metastases Treated with Stereotactic Radiosurgery and Concurrent Pembrolizumab Display Marked Regression; Efficacy and Safety of Combined Treatment  
  Jedd D Wolchok, Kathryn Beal, Yoshiya Yamada, Michael A Postow, BioMed Central

Lectures

• Treatment of Advanced Melanoma After Progression on PD-1 Blockade 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiotherapy (RT) in patients with metastatic melanoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Melanoma and Other Skin Cancers. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 1) 
  2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018